SODIUM NITROPRUSSIDE FOR INJECTION 25 MG — DIN 02450089
SODIUM NITROPRUSSIDE : 25 MG · STERIMAX INC · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is SODIUM NITROPRUSSIDE FOR INJECTION?
SODIUM NITROPRUSSIDE FOR INJECTION 25 MG contains SODIUM NITROPRUSSIDE : 25 MG. It is listed in the Health Canada Drug Product Database under DIN 02450089, held by STERIMAX INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 26-Apr-2021. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is SODIUM NITROPRUSSIDE FOR INJECTION used for?
Treatment of acute hypertension refractory to standard measures; producing controlled hypotension during anesthesia to reduce bleeding in surgical procedures.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Is there a generic Nitroprusside in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Nitroprusside, across 6 DINs, of which 4 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| DR REDDY'S LABORATORIES LTD | 1 | 1 | SODIUM NITROPRUSSIDE FOR INJECTION | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 1 | 1 | SODIUM NITROPRUSSIDE FOR INJECTION | Sourceable in Canada |
| MARCAN PHARMACEUTICALS INC | 1 | 1 | SODIUM NITROPRUSSIDE FOR INJECTION | Sourceable in Canada |
| STERIMAX INC | 1 | 1 | SODIUM NITROPRUSSIDE FOR INJECTION | Sourceable in Canada |
| HOSPIRA HEALTHCARE ULC | 1 | 0 | NIPRIDE | No marketed DIN |
| PFIZER CANADA ULC | 1 | 0 | NIPRIDE | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 25 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAVENOUS |
| Pack configuration (monograph) | Single-use amber glass vials in 50 mg/2 mL format (25 mg/mL). Includes supplied opaque sleeve for light protection. |
| Storage | Store at controlled room temperature (15-30°C). Protect from light. Reconstituted/diluted solution stable for 24 hours. |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Nitroprusside |
|---|---|
| ATC code | C02DD01 |
| AHFS class | 24:08.20 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02450089 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2450089 |
| Brand name | SODIUM NITROPRUSSIDE FOR INJECTION |
| Generic / active ingredient | SODIUM NITROPRUSSIDE : 25 MG |
| Market authorization holder | STERIMAX INC |
| Health Canada schedule | Prescription |
| ATC code | C02DD01 |
| ATC anatomical main group | C — Cardiovascular system |
| ATC therapeutic subgroup | C02DD |
| Current status | MARKETED |
| Status date | 26-Apr-2021 |
| Original market date | 2021-04-26 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
How is it administered?
Must be diluted in 5% Dextrose. Average dose 3 mcg/kg/min (range 0.5-8 mcg/kg/min). Administer via infusion pump. Do not exceed 8 mcg/kg/min for more than 10 minutes.
Included because it drives pack selection and wastage. Consult the monograph.
Contraindications
Hypersensitivity; compensatory hypertension; physically poor-risk patients (ASA Risk 5); uncorrected anemia/hypovolemia; inadequate cerebral circulation; liver/severe renal disease (for anesthesia).
Warnings and precautions
Serious Warning: Not for direct injection. Can cause precipitous BP decrease and fatal cyanide poisoning. Monitor acid-base balance. Discontinue if resistance/tachyphylaxis occurs.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
4 of 6 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| SODIUM NITROPRUSSIDE FOR INJECTION | 25 MG | SOLUTION | MARCAN PHARMACEUTICALS INC | MARKETED | 02479109 |
| SODIUM NITROPRUSSIDE FOR INJECTION | 25 MG | SOLUTION | DR REDDY'S LABORATORIES LTD | MARKETED | 02507404 |
| SODIUM NITROPRUSSIDE FOR INJECTION | 25 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | 02542129 |
| NIPRIDE | 50 MG | POWDER FOR SOLUTION | HOSPIRA HEALTHCARE ULC | CANCELLED POST MARKET | 00336459 |
| NIPRIDE | 25 MG | SOLUTION | PFIZER CANADA ULC | CANCELLED POST MARKET | 02361736 |
2 · Same class — other molecules in ATC C02DD
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Nitroprusside | NIPRIDE · SODIUM NITROPRUSSIDE FOR INJECTION | 6 | 4 | Yes |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC C02D
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| C02DB | Hydralazine | 34 | 14 |
| C02DC | Minoxidil | 2 | 2 |
| C02DA | Diazoxide | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is SODIUM NITROPRUSSIDE FOR INJECTION called?
The same molecule, Nitroprusside, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Nipruss | Latin | Iceland |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.